Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodixanol SCHEMBL28086309 | 0.93 | LMNA (0.84) | LMNACYP2C19HIF1A | |
| Iopentol SCHEMBL24471 | 0.92 | LMNA (0.82) | LMNACYP2C19HIF1AALDH1A1 | |
| Iopentol SCHEMBL8845316 | 0.92 | LMNA (0.82) | LMNACYP2C19HIF1AALDH1A1 | |
| Iopentol SCHEMBL14740647 | 0.91 | CYP2C19 (0.84) | LMNACYP2C19HIF1A | |
| SCHEMBL10058205 | 0.90 | LMNA (0.76) | LMNACYP2C19HIF1AALDH1A1 | |
| SCHEMBL9564078 | 0.88 | LMNA (0.76) | LMNACYP2C19HIF1A | |
| SCHEMBL12855756 | 0.86 | LMNA (0.84) | LMNACYP2C19HIF1A | |
| SCHEMBL12855754 | 0.86 | LMNA (0.84) | LMNACYP2C19HIF1A | |
| SCHEMBL12855752 | 0.86 | LMNA (0.84) | LMNACYP2C19HIF1A | |
| Iodixanol SCHEMBL37712 | 0.86 | LMNA (1.00) | LMNACYP2C19HIF1AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | disclosed |
| EP-2245004-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | LMNA 1002/4885CYP2C19 2085/4885HIF1A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.